Changes in innate populations and CD8 T cells are maintained in patients on DH for 12 months. Flow cytometric analysis of CD4⁺ and CD8⁺ memory subsets (A), NK cells, CD16⁺ NK cells, γδ T cells, and CD14⁺ cells (B) at baseline, 12 months (M12), start of DH, and 12 to 18 months off study drugs (DH+12M; n = 4). P values from a 2-way analysis of variance with Dunnett’s multiple comparisons to B (A) and Kruskal-Wallis test Dunn’s multiple comparisons to B (B). (C) NanoString myeloid inflammation analysis in patients on DH (n = 4). *P < .05, **P < .01, ***P < .001.